Clinical Research Directory
Browse clinical research sites, groups, and studies.
Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd.
Summary
This study plans to enroll participants with previously treated advanced pancreatic cancer and harbor centrally confirmed KRAS G12D mutation. Eligible participants will be randomized 1:1 to DN022150 Monotherapy or Investigator's Choice Chemotherapy
Official title: A Phase 3, Multicenter, Open-Label, Randomized, Controlled Trial of DN022150 Monotherapy Versus Investigator's Choice Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
360
Start Date
2026-09
Completion Date
2028-12
Last Updated
2026-07-08
Healthy Volunteers
No
Conditions
Interventions
DN022150
iv QW 28-day/cycle
Chemotherapy
Investigator's Choice of Chemotherapy: nal-IRI + 5-FU/LV, AG, or S-1